Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00749749 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of the CollaRx Bupivacaine Implant Compared to the ON-Q Painbuster Following Abdominal Hysterectomy
A Phase 2 study, sponsored by Innocoll.
- Completed
- Registry status
- Phase 2
- Development phase
- 27
- Enrollment target
NCT00749749 is a Phase 2 study that has completed, run by Innocoll. The registered enrollment target is 27 participants.
The verdict
NCT00749749, a Phase 2 study, has completed, sponsored by Innocoll.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 27 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether the CollaRx Bupivacaine Implant is safe and effective in reducing the amount of narcotic pain medication needed to control pain during the first 96 hours after abdominal hysterectomy when compared to the ON-Q PainBuster Post-op Pain Relief System.
Interventions
- DRUG Bupivacaine Collagen Sponge (CollaRx Bupivacaine Implant)
- DRUG ON-Q PainBuster Post-op Pain relief System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2008-09-10 |
| Est. Completion | 2008-12-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00749749
The ClinicalTrials.gov registry entry for NCT00749749 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Innocoll, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Bupivacaine Collagen Sponge (CollaRx Bupivacaine Implant) is the first listed.
NCT00749749 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00749749 about?
NCT00749749 is a clinical study titled "Efficacy and Safety of the CollaRx Bupivacaine Implant Compared to the ON-Q Painbuster Following Abdominal Hysterectomy". The purpose of this study is to determine whether the CollaRx Bupivacaine Implant is safe and effective in reducing the amount of narcotic pain medication needed to control pain during the first 96 hours after abdominal hysterectomy when compared to the ON-Q PainBuster Post-op Pain Relief System.
What is the current status of trial NCT00749749?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 27 participants. The study started on 2008-09-10. Estimated completion is 2008-12-22.
What interventions are being tested in trial NCT00749749?
The interventions under investigation include: Bupivacaine Collagen Sponge (CollaRx Bupivacaine Implant) (DRUG), ON-Q PainBuster Post-op Pain relief System (DRUG).
Who is sponsoring clinical trial NCT00749749?
This trial is sponsored by Innocoll, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.